Qing Fang1, Anna Flavia Figueredo Benedetti2, Qianyi Ma1, Louise Gregory3, Jun Z Li1, Mehul Dattani3, Abdollah Sadeghi-Nejad4, Ivo J P Arnhold2, Berenice Bilharinho Mendonca2, Sally A Camper1, Luciani R Carvalho2. 1. Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA. 2. Division of Endocrinology, Unit of Endocrinology and Development, Laboratory of Hormones and Molecular Genetics, Clinical Hospital of the Faculty of Medicine of the University of São Paulo, São Paulo, Brazil. 3. Developmental Endocrinology Research Group, Section of Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme, University College London, Institute of Child Health, London, UK. 4. Division of Pediatric Endocrinology, Floating Hospital for Children at Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
Abstract
INTRODUCTION: Mutations in the transcription factor HESX1 can cause isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiency (CPHD) with or without septo-optic dysplasia (SOD). So far there is no clear genotype-phenotype correlation. PATIENTS AND RESULTS: We report four different recessive loss-of-function mutations in three unrelated families with CPHD and no midline defects or SOD. A homozygous p.R160C mutation was found by Sanger sequencing in two siblings from a consanguineous family. These patients presented with ACTH, TSH and GH deficiencies, severe anterior pituitary hypoplasia (APH) or pituitary aplasia (PA) and normal posterior pituitary. The p.R160C mutation was previously reported in a case with SOD, CPHD and ectopic posterior pituitary (EPP). Using exome sequencing, a homozygous p.I26T mutation was found in a Brazilian patient born to consanguineous parents. This patient had evolving CPHD, normal ACTH, APH and normal posterior pituitary (NPP). A previously reported patient homozygous for p.I26T had evolving CPHD and EPP. Finally, we identified compound heterozygous mutations in HESX1, p.[R159W];[R160H], in a patient with PA and CPHD. We showed that both of these mutations abrogate the ability of HESX1 to repress PROP1-mediated transcriptional activation. A patient homozygous for p.R160H was previously reported in a patient with CPHD, EPP, APH. CONCLUSION: These three examples demonstrate that HESX1 mutations cause variable clinical features in patients, which suggests an influence of modifier genes or environmental factors on the phenotype.
INTRODUCTION: Mutations in the transcription factor HESX1 can cause isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiency (CPHD) with or without septo-optic dysplasia (SOD). So far there is no clear genotype-phenotype correlation. PATIENTS AND RESULTS: We report four different recessive loss-of-function mutations in three unrelated families with CPHD and no midline defects or SOD. A homozygous p.R160C mutation was found by Sanger sequencing in two siblings from a consanguineous family. These patients presented with ACTH, TSH and GH deficiencies, severe anterior pituitary hypoplasia (APH) or pituitary aplasia (PA) and normal posterior pituitary. The p.R160C mutation was previously reported in a case with SOD, CPHD and ectopic posterior pituitary (EPP). Using exome sequencing, a homozygous p.I26T mutation was found in a Brazilian patient born to consanguineous parents. This patient had evolving CPHD, normal ACTH, APH and normal posterior pituitary (NPP). A previously reported patient homozygous for p.I26T had evolving CPHD and EPP. Finally, we identified compound heterozygous mutations in HESX1, p.[R159W];[R160H], in a patient with PA and CPHD. We showed that both of these mutations abrogate the ability of HESX1 to repress PROP1-mediated transcriptional activation. A patient homozygous for p.R160H was previously reported in a patient with CPHD, EPP, APH. CONCLUSION: These three examples demonstrate that HESX1 mutations cause variable clinical features in patients, which suggests an influence of modifier genes or environmental factors on the phenotype.
Authors: P Q Thomas; M T Dattani; J M Brickman; D McNay; G Warne; M Zacharin; F Cameron; J Hurst; K Woods; D Dunger; R Stanhope; S Forrest; I C Robinson; R S Beddington Journal: Hum Mol Genet Date: 2001-01-01 Impact factor: 6.150
Authors: Ender Karaca; Ramazan Buyukkaya; Davut Pehlivan; Wu-Lin Charng; Kursat O Yaykasli; Yavuz Bayram; Tomasz Gambin; Marjorie Withers; Mehmed M Atik; Ilknur Arslanoglu; Semih Bolu; Serkan Erdin; Ayla Buyukkaya; Emine Yaykasli; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski Journal: J Clin Endocrinol Metab Date: 2015-01 Impact factor: 5.958
Authors: Ezat Sajedi; Carles Gaston-Massuet; Massimo Signore; Cynthia L Andoniadou; Daniel Kelberman; Sandra Castro; Heather C Etchevers; Dianne Gerrelli; Mehul T Dattani; Juan Pedro Martinez-Barbera Journal: Dis Model Mech Date: 2008-11-06 Impact factor: 5.758
Authors: Carles Gaston-Massuet; Cynthia L Andoniadou; Massimo Signore; Ezat Sajedi; Sophie Bird; James M A Turner; Juan Pedro Martinez-Barbera Journal: Dev Biol Date: 2008-08-18 Impact factor: 3.582
Authors: María Arnedo; Sebastián Menao; Beatriz Puisac; María E Teresa-Rodrigo; María C Gil-Rodríguez; Eduardo López-Viñas; Paulino Gómez-Puertas; Nuria Casals; César H Casale; Fausto G Hegardt; Juan Pié Journal: J Lipid Res Date: 2012-07-30 Impact factor: 5.922
Authors: Marc-Olivier Turgeon; Tanya L Silander; Denica Doycheva; Xiao-Hui Liao; Marc Rigden; Luisina Ongaro; Xiang Zhou; Sjoerd D Joustra; Jan M Wit; Mike G Wade; Heike Heuer; Samuel Refetoff; Daniel J Bernard Journal: Endocrinology Date: 2017-04-01 Impact factor: 4.736
Authors: Tatiane S Silva; Fabio R Faucz; Laura C Hernández-Ramírez; Nathan Pankratz; John Lane; Denise M Kay; Arthur Lyra; Cristiane Kochi; Constantine A Stratakis; Carlos A Longui; James L Mills Journal: J Endocr Soc Date: 2022-08-11
Authors: Qing Fang; Akima S George; Michelle L Brinkmeier; Amanda H Mortensen; Peter Gergics; Leonard Y M Cheung; Alexandre Z Daly; Adnan Ajmal; María Ines Pérez Millán; A Bilge Ozel; Jacob O Kitzman; Ryan E Mills; Jun Z Li; Sally A Camper Journal: Endocr Rev Date: 2016-11-09 Impact factor: 19.871
Authors: Louise C Gregory; Peter Gergics; Marilena Nakaguma; Hironori Bando; Giuseppa Patti; Mark J McCabe; Qing Fang; Qianyi Ma; Ayse Bilge Ozel; Jun Z Li; Michele Moreira Poina; Alexander A L Jorge; Anna F Figueredo Benedetti; Antonio M Lerario; Ivo J P Arnhold; Berenice B Mendonca; Mohamad Maghnie; Sally A Camper; Luciani R S Carvalho; Mehul T Dattani Journal: Eur J Endocrinol Date: 2021-05-25 Impact factor: 6.558
Authors: Sebastian Alexis Vishnopolska; Maria Florencia Mercogliano; Maria Andrea Camilletti; Amanda Helen Mortensen; Debora Braslavsky; Ana Keselman; Ignacio Bergadá; Federico Olivieri; Lucas Miranda; Roxana Marino; Pablo Ramírez; Natalia Pérez Garrido; Helen Patiño Mejia; Marta Ciaccio; Maria Isabel Di Palma; Alicia Belgorosky; Marcelo Adrian Martí; Jacob Otto Kitzman; Sally Ann Camper; Maria Ines Pérez-Millán Journal: J Clin Endocrinol Metab Date: 2021-06-16 Impact factor: 6.134